A new House bill would require dietary supplement manufacturers to register products with FDA, reigniting debate between industry groups over transparency, regulatory burden, and the future of DSHEA oversight.
The Government of India's restriction on ashwagandha leaves in nutritional supplements is sparking industry debate. Experts weigh safety, science, and supply chain impacts of the root-only directive.
AHPA, CRN, and NPA react to the introduction of the Dietary Supplement Listing Act of 2026, renewing a debate within the natural products industry over the role of a mandatory product listing and dietary supplement oversight.
